BDX

In the past six months, BDX stock has been impacted by several key events. BD reported stronger-than-expected Q2 fiscal 2026 results and raised its full-year adjusted EPS guidance, leading to a stock price increase. BD executed a $2.0 billion accelerated share repurchase program and retired $2.1 billion of debt, which was viewed positively by investors. Vitor Roque was named Executive Vice President and Chief Financial Officer. BD completed the spin-off of its Biosciences and Diagnostic Solutions business, leading to a downward revision of full-year earnings guidance and causing some intraday volatility. Analysts have adjusted their price targets for BDX, with some raising targets following the positive Q2 results.